Oral pharmaceutical composition containing polyethylene...

Details Oral pharmaceutical composition containing polyethylene... Oral pharmaceutical composition containing polyethylene...

A - Human Necessities

61

K

A61K 39/44 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2122374

2122374 9308838 PCTABS00021 Polyethylene glycol serum immunoglobulin conjugates exhibit substantial resistance to degradation by intestinal enzyme while retaining their immuno-activity. Thus, PEG-IgG or PEG-IgA conjugates can be used as orally administered therapeutics to treat patients with gastrointestinal immunodeficiency to reconstitute secretory immunity. Preferred conjugates are made by reacting activated PEG and IgG in ratios of from 1:5 to 1:1000 such that less than about 27 % of the IgG lysine residues are bonded to the PEG. The conjugates are advantageously formulated into a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable oral carrier. Particularly for administration to infants, a preferred oral carrier is milk.

Affiliated with

Also associated with

Rating

Oral pharmaceutical composition containing polyethylene... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral pharmaceutical composition containing polyethylene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral pharmaceutical composition containing polyethylene... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1412288